正海生物
(300653)
| 流通市值：37.12亿 | | | 总市值：37.12亿 |
| 流通股本：1.80亿 | | | 总股本：1.80亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 66,588,190.74 | 116,837,501.64 | 145,536,579.65 | 96,307,854.52 |
| 应收票据及应收账款 | 52,834,184.4 | 48,826,312.59 | 54,793,582.51 | 56,289,866.25 |
| 其中：应收票据 | 331,161.6 | 331,161.6 | - | 34,446.36 |
| 应收账款 | 52,503,022.8 | 48,495,150.99 | 54,793,582.51 | 56,255,419.89 |
| 应收款项融资 | 1,361,635.8 | 1,944,481.9 | 2,080,095.6 | 1,979,698.38 |
| 预付款项 | 4,415,997.63 | 3,441,253.12 | 5,653,513.67 | 2,831,627.65 |
| 其他应收款合计 | 1,269,434.17 | 636,852.06 | 1,380,882.21 | 1,455,426.46 |
| 存货 | 28,257,139.6 | 35,183,154.31 | 34,885,808.22 | 33,715,846.15 |
| 其他流动资产 | - | 401,570.02 | 72,340.25 | 1,142,288.18 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 749,093,740.23 | 712,700,493.26 | 708,663,060.52 | 686,057,915.03 |
| 非流动资产: | | | | |
| 投资性房地产 | 66,322.85 | 66,322.85 | 66,322.85 | 73,783.38 |
| 固定资产 | 224,843,942.51 | 228,744,485.59 | 231,275,943.19 | 231,367,192.91 |
| 在建工程 | 1,226,512.28 | 1,344,330.41 | 2,999,515.98 | 6,957,687.93 |
| 无形资产 | 31,871,459.89 | 32,531,600.77 | 32,997,608.64 | 33,689,999.91 |
| 长期待摊费用 | - | 15,880.52 | 39,679.75 | 76,423.51 |
| 递延所得税资产 | 2,242,178.32 | 2,327,839.65 | 1,016,662.25 | 1,623,928.32 |
| 其他非流动资产 | 2,356,664.39 | 2,382,668.94 | 342,275.57 | 143,097.92 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 262,607,080.24 | 267,413,128.73 | 268,738,008.23 | 273,932,113.88 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 1,011,700,820.47 | 980,113,621.99 | 977,401,068.75 | 959,990,028.91 |
| 流动负债: | | | | |
| 应付票据及应付账款 | 16,770,442.7 | 21,818,777.78 | 22,205,669.62 | 23,814,081.89 |
| 其中：应付票据 | 4,187,004.86 | 5,158,073.65 | 4,498,934.82 | 4,902,486.74 |
| 应付账款 | 12,583,437.84 | 16,660,704.13 | 17,706,734.8 | 18,911,595.15 |
| 合同负债 | 13,399,499.91 | 13,938,496.36 | 4,130,688.44 | 6,387,950.22 |
| 应付职工薪酬 | 10,505,942.77 | 10,460,971.86 | 14,582,332.44 | 11,537,469.88 |
| 应交税费 | 10,960,242.04 | 3,138,154.98 | 7,316,838.47 | 6,869,139.95 |
| 其他应付款合计 | 33,965,588.98 | 31,325,220.85 | 23,030,042.96 | 21,079,109.41 |
| 其他流动负债 | 462,315.2 | 107,647.87 | 93,453.8 | 155,146.47 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 86,064,031.6 | 80,789,269.7 | 71,359,025.73 | 69,842,897.82 |
| 非流动负债: | | | | |
| 递延收益 | 4,719,276.08 | 4,874,231.24 | 5,015,217.76 | 8,718,309.6 |
| 递延所得税负债 | 5,506,657.86 | 5,665,989.31 | 6,176,383.06 | 6,317,298.85 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 10,225,933.94 | 10,540,220.55 | 11,191,600.82 | 15,035,608.45 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 96,289,965.54 | 91,329,490.25 | 82,550,626.55 | 84,878,506.27 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 180,000,000 | 180,000,000 | 180,000,000 | 180,000,000 |
| 资本公积 | 169,418,284.73 | 169,418,284.73 | 169,418,284.73 | 169,418,284.73 |
| 减:库存股 | 49,920,352.99 | 49,920,352.99 | 34,279,266.49 | 14,994,594.38 |
| 盈余公积 | 99,202,234.55 | 99,202,234.55 | 99,202,234.55 | 99,202,234.55 |
| 未分配利润 | 516,710,688.64 | 490,083,965.45 | 480,509,189.41 | 441,485,597.74 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 915,410,854.93 | 888,784,131.74 | 894,850,442.2 | 875,111,522.64 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 915,410,854.93 | 888,784,131.74 | 894,850,442.2 | 875,111,522.64 |
| 负债和股东权益合计 | 1,011,700,820.47 | 980,113,621.99 | 977,401,068.75 | 959,990,028.91 |
| 公告日期 | 2025-04-22 | 2025-04-15 | 2024-10-23 | 2024-08-06 |
| 审计意见(境内) | | 标准无保留意见 | | |